文献速递造血干细胞移植与细胞治疗MDS 与骨髓增殖性肿瘤淋巴瘤

克隆性造血与淋巴瘤自体干细胞移植后不良结局相关

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
PubMed 文献 · J Clin Oncol · 2017-01-09

研究对12例淋巴瘤自体移植后发生治疗相关髓系肿瘤的患者行全外显子测序,并对401例2003至2010年间接受自体移植的非霍奇金淋巴瘤患者行靶向测序。移植时存在克隆性造血与治疗相关髓系肿瘤累积发生率升高及总生存更差相关。

要点

  • 移植时克隆性造血与治疗相关髓系肿瘤10年累积发生率升高相关(14.1% vs 4.3%,P=0.002)。
  • 移植时克隆性造血患者10年总生存更差(30.4% vs 60.9%,P<0.001)。
  • 克隆性造血与治疗相关髓系肿瘤及心血管疾病死亡风险升高相关。

核心结论

  • 在因淋巴瘤接受自体干细胞移植的患者中,移植时存在克隆性造血与更差的总生存及治疗相关髓系肿瘤风险升高相关。

研究设计与样本

  • 对12例因霍奇金淋巴瘤或非霍奇金淋巴瘤接受自体移植后发生治疗相关髓系肿瘤的患者,进行移植前后样本的全外显子测序。
  • 对2003年至2010年间接受自体干细胞移植的401例非霍奇金淋巴瘤患者的冷冻自体干细胞产品进行靶向测序。

主要发现

  • 全外显子测序队列12例患者中,6例的治疗相关髓系肿瘤标本中发现的突变在移植前标本中也可检测到。
  • 靶向测序队列中120例(29.9%)在移植时存在克隆性造血,其治疗相关髓系肿瘤10年累积发生率为14.1%,无克隆性造血者为4.3%(P=0.002)。
  • 克隆性造血患者10年总生存率为30.4%,无克隆性造血者为60.9%(P<0.001),且克隆性造血与治疗相关髓系肿瘤及心血管疾病死亡风险升高相关。

关键数值与推荐

  • 克隆性造血定义为移植时检测到体细胞突变,靶向测序队列中120例(29.9%)存在克隆性造血。
  • 治疗相关髓系肿瘤10年累积发生率:克隆性造血患者14.1% vs 无克隆性造血患者4.3%(P=0.002)。
  • 10年总生存率:克隆性造血患者30.4% vs 无克隆性造血患者60.9%(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by somatic mutations in the blood of otherwise healthy adults. We hypothesized that in patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at the time of ASCT would be associated with an increased risk of myelodysplastic syndrome and acute myeloid leukemia, collectively termed therapy-related myeloid neoplasm (TMN), and other adverse outcomes. Methods We performed whole-exome sequencing on pre- and post-ASCT samples from 12 patients who developed TMN after autologous transplantation for Hodgkin lymphoma or non-Hodgkin lymphoma and targeted sequencing on cryopreserved aliquots of autologous stem-cell products from 401 patients who underwent ASCT for non-Hodgkin lymphoma between 2003 and 2010. We assessed the effect of CHIP at the time of ASCT on subsequent outcomes, including TMN, cause-specific mortality, and overall survival. Results For six of 12 patients in the exome sequencing cohort, mutations found in the TMN specimen were also detectable in the pre-ASCT specimen. In the targeted sequencing cohort, 120 patients (29.9%) had CHIP at the time of ASCT, which was associated with an increased rate of TMN (10-year cumulative incidence, 14.1% v 4.3% for those with and without CHIP, respectively; P = .002). Patients with CHIP had significantly inferior overall survival compared with those without CHIP (10-year overall survival, 30.4% v 60.9%, respectively; P < .001), including increased risk of death from TMN and cardiovascular disease. Conclusion In patients undergoing ASCT for lymphoma, CHIP at the time of transplantation is associated with inferior survival and increased risk of TMN.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017. PMID: 28068180. doi:10.1200/JCO.2016.71.6712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。